Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...

Gilead Sciences has taken a major step towards increasing global access to HIV prevention with the signing ... compared to once-daily oral Truvada and background HIV incidence rates, prompting ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly effective medicine. However, Ben Hargreaves finds that the company’s ...

The Truvada (TDF-FTC) arm was continued until ... A women-controlled method to prevent HIV infection is urgently needed. Microbicides provide real potential to influence the course of the HIV ...

The Trump administration has made some concessions to the halt placed on distributions of global HIV treatments via ...

The State Department issued a waiver for lifesaving aid, but HIV clinics remain shut and uncertainty lingers over the future ...

The Trump administration's aid freeze affects HIV treatment access. Find out how organizations are coping with the directive.

As a result of the new administration's actions, health centers funded by PEPFAR, the U.S. President's Emergency Plan for ...

Clinical Trial Reveals Twice-Yearly Injection to Be 96% Effective in HIV Prevention Nov. 27, 2024 — Recent results from a recent clinical trial indicate that a twice-yearly injection of ...

British Prime Minister Keir Starmer’s decision to review the controversial Prevent programme comes too late for the victims of its failures. After the Southport stabbings last summer ...

Following his arrest in July, an urgent Prevent review was carried out over the summer which found that while there was evidence he had an obsession with violence, his case was not escalated as he ...